Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Por um escritor misterioso
Descrição
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two – topic of research paper in Biological sciences. Download scholarly article PDF and read for
Proteomics and Beyond: Cell Decision-Making Shaped by Reactive Electrophiles: Trends in Biochemical Sciences
A guide to enzyme kinetics in early drug discovery - Srinivasan - 2023 - The FEBS Journal - Wiley Online Library
Pharmaceuticals, Free Full-Text
Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors
Kinase drug discovery modern approaches 978-1-78801-309-3, 1788013093, 978-1-78801-563-9, 1788015630, 978-1-78801-083-2
Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen
Advances in covalent drug discovery
Frontiers Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
de
por adulto (o preço varia de acordo com o tamanho do grupo)
